CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
英文原题：Elevated serum levels of soluble B-cell maturation antigen as a prognostic biomarker for multiple myeloma.
Elevated serum levels of soluble B-cell maturation antigen as a prognostic biomarker for multiple myeloma.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
血清B细胞成熟抗原（sBCMA）水平可作为多发性骨髓瘤（MM）的敏感生物标志物。在研究环境中，sBCMA水平可通过酶联免疫吸附试验（ELISA）准确检测，但该方法尚未获批用于临床。
在此，我们采用一种新型化学发光法评估了759份血清样本中的sBCMA水平，样本来自17名健康供者和443例浆细胞（PC）疾病患者，包括AL淀粉样变性、POEMS综合征和MM。与健康供者和罕见PC疾病患者相比，新诊断MM患者的血清BCMA水平升高16.1倍。
具体而言，疾病进展期患者的sBCMA水平比治疗达到部分缓解或以上者高64.6倍。sBCMA水平还与MM患者的缓解深度呈负相关。在新诊断和复发MM患者中，sBCMA水平低于中位值者的生存期显著长于高于中位值者。
我们通过将sBCMA水平纳入第二版修订国际分期系统（R2-ISS），进一步优化了生存预测的准确性。我们的研究结果证明，这种新型化学发光法用于检测临床样本中的sBCMA水平灵敏且实用，并证实sBCMA可能作为MM的独立预后生物标志物。
Serum B-cell maturation antigen (sBCMA) levels can serve as a sensitive biomarker in multiple myeloma (MM). In the research setting, sBCMA levels can be accurately detected by enzyme-linked immunosorbent assay (ELISA), but the approach has not been approved for clinical use.
Here, we used a novel chemiluminescence method to assess sBCMA levels in 759 serum samples from 17 healthy donors and 443 patients with plasma cell (PC) diseases including AL amyloidosis, POEMS syndrome, and MM. Serum BCMA levels were elevated 16. 1-fold in patients with newly diagnosed MM compared to healthy donors and rare PC diseases patients. Specifically, the sBCMA levels in patients with progressive disease were 64.
6-fold higher than those who showed partial response or above to treatment. The sBCMA level also correlated negatively with the response depth of MM patients. In newly diagnosed and relapsed MM patients, survival was significantly longer among those subjects whose sBCMA levels are below the median levels compared with those above the median value.
We optimized the accuracy of the survival prediction further by integrating sBCMA level into the Second Revised International Staging System (R2-ISS).
Our findings provide evidence that the novel chemiluminescence method is sensitive and practical for measuring sBCMA levels in clinical samples and confirm that sBCMA might serve as an independent prognostic biomarker for MM.
MEMBER ACCOUNT
登录成功会直接打开下一页。
